Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus THIOTHIXENE HYDROCHLORIDE INTENSOL.
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus THIOTHIXENE HYDROCHLORIDE INTENSOL.
FLUPHENAZINE DECANOATE vs THIOTHIXENE HYDROCHLORIDE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic. It exerts its effects by blocking postsynaptic dopamine D2 receptors in the mesolimbic pathway, and also has antagonistic activity at alpha-1 adrenergic, muscarinic, and histamine H1 receptors, contributing to its side effect profile.
Thiothixene is a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the central nervous system, particularly in the mesolimbic and mesocortical pathways. It also has affinity for serotonin 5-HT2, histamine H1, and alpha-1 adrenergic receptors, contributing to its therapeutic and adverse effects.
12.5-25 mg deep IM injection every 2-4 weeks, not exceeding 100 mg per dose.
Initial: 2 mg orally three times daily. Maintenance: 15-30 mg orally daily in divided doses. Maximum: 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 7-21 days) following IM injection, reflecting slow release from depot and prolonged redistribution.
Terminal elimination half-life ranges from 26 to 36 hours in healthy adults, allowing for once-daily dosing in maintenance therapy. In chronic use, the half-life may be prolonged due to accumulation.
Primarily renal (metabolites) and fecal (biliary). Estimated 50% renal, 50% fecal as metabolites.
Primarily renal and biliary; about 50-60% of a single dose is excreted in the urine as metabolites and unchanged drug within 48 hours, with approximately 30-40% eliminated in feces via biliary secretion. Less than 1% of the parent drug is excreted unchanged in urine.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic